EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence

Mohit Mathur, Tak Mao Chan, Kook-Hwan Oh, Laura Kooienga, Min Zhuo iD, Cibele S Pinto, Bobby Chacko

Journal of Clinical Medicine · 04.11.2023 · 12 (21) · 6927

DOI: 10.3390/jcm12216927 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.11.2023. Verfasst von Mohit Mathur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Visterra, Inc., Waltham, MA 02451, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmamaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A PRoliferation-Inducing Ligand (APRIL), the thirteenth member of the tumor necrosis factor superfamily, plays a key role in the regulation of activated B cells, the survival of long-lived plasma cells, and immunoglobulin (Ig) isotype class switching. Several lines of evidence have implicated APRIL in the pathogenesis of IgA nephropathy (IgAN). Globally, IgAN is the most common primary glomerulonephritis, and it can progress to end-stage kidney disease; yet, disease-modifying treatments for this condition have historically been lacking. The preliminary data in ongoing clinical trials indicate that APRIL inhibition can reduce proteinuria and slow the rate of kidney disease progression by acting at an upstream level in IgAN pathogenesis. In this review, we examine what is known about the physiologic roles of APRIL and evaluate the experimental and epidemiological evidence describing how these normal biologic processes are thought to be subverted in IgAN. The weight of the preclinical, clinical, and genetic data supporting a key role for APRIL in IgAN has galvanized pharmacologic research, and several anti-APRIL drug candidates have now entered clinical development for IgAN. Herein, we present an overview of the clinical results to date. Finally, we explore where more research and evidence are needed to transform potential therapies into clinical benefits for patients with IgAN.

Schlagwörter

Stichwörter der Autor:innen

A PRoliferation-Inducing LigandAPRILB cellsBAFFBCMAIgA nephropathyTACITNFSF13

Autor:innen und Institutionen

  • Visterra, Inc., Waltham, MA 02451, USA.
  • Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
  • Colorado Kidney and Vascular Care, Denver, CO 80012, USA.
  • Division of Renal Medicine, Department of Medicine Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ 08540, USA.

ORCID-Profile: Min Zhuo

Förderung

  • Otsuka Pharmamaceutical Development & Commercialization, Inc.
  • Otsuka Pharmaceutical Development & Commercialization, Inc.

Zitieren

APA

Mathur, M., Chan, T. M., Oh, K. H., Kooienga, L., Zhuo, M., Pinto, C. S., & Chacko, B. (2023). A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. Journal of Clinical Medicine, 12(21), 6927. https://doi.org/10.3390/jcm12216927

Vancouver

Mathur M, Chan TM, Oh KH, Kooienga L, Zhuo M, Pinto CS, et al. A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. Journal of Clinical Medicine. 2023;12(21):6927. doi:10.3390/jcm12216927

BibTeX
@article{Mathur2023,
  author = {Mathur, Mohit and Chan, Tak Mao and Oh, Kook-Hwan and Kooienga, Laura and Zhuo, Min and Pinto, Cibele S and Chacko, Bobby},
  title = {A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {21},
  pages = {6927},
  doi = {10.3390/jcm12216927}
}
Kostenlos starten →